Filaggrin

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Retrieved on: 
Thursday, April 29, 2021
Type I hypersensitivity, Atopic dermatitis, Dermatitis, Atopy, Filaggrin, Branches of biology

KARE enrolled 64% of patients characterized as mild-to-moderate (BSA10%).

Key Points: 
  • KARE enrolled 64% of patients characterized as mild-to-moderate (BSA10%).
  • A prespecified interim conditional power assessment was conducted after approximately 50% of the originally targeted patient number completed the designated 12-week treatment period.
  • Pruritus prevalence in AD patients is greater than 80% and greatly impairs the quality of life of AD patients by causing sleep and psychological disturbance.
  • 2008;8(4):306-311.\nThyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis.

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis

Retrieved on: 
Monday, April 12, 2021
Medical specialties, Type I hypersensitivity, Immunology, Clinical medicine, Atopy, Atopic dermatitis, Dermatitis, Allergy, Filaggrin

In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.

Key Points: 
  • In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.
  • The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis.\nSIAF, based in Davos, is a world leader within applied allergy and asthma research.
  • Skin barrier assessment shows potential to be clinically useful for early prediction of disease development, improved diagnosis, disease follow-up and therapy evaluation.\nThis study shows that the Nevisense method can directly assess the status of epithelial barrier using electrical impedance spectroscopy (EIS).
  • Furthermore, copy numbers of filaggrin, an essential skin barrier molecule significantly correlated with EIS on non-lesional skin of patients.

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis

Retrieved on: 
Monday, April 12, 2021
Medical specialties, Type I hypersensitivity, Immunology, Clinical medicine, Atopy, Atopic dermatitis, Dermatitis, Allergy, Filaggrin

In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.

Key Points: 
  • In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.
  • The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis.\nSIAF, based in Davos, is a world leader within applied allergy and asthma research.
  • Skin barrier assessment shows potential to be clinically useful for early prediction of disease development, improved diagnosis, disease follow-up and therapy evaluation.\nThis study shows that the Nevisense method can directly assess the status of epithelial barrier using electrical impedance spectroscopy (EIS).
  • Furthermore, copy numbers of filaggrin, an essential skin barrier molecule significantly correlated with EIS on non-lesional skin of patients.

Angie Seelal, R-PAC with Advanced Dermatology PC, Shares Tips on Managing Atopic Dermatitis

Retrieved on: 
Wednesday, January 29, 2020
RTT, Type I hypersensitivity, Dermatitis, Atopy, Atopic dermatitis, Filaggrin, Branches of biology

"We've seen rates of atopic dermatitis or 'AD' climb," notes Angie Seelal, R-PAC specializing in dermatology with Advanced Dermatology PC .

Key Points: 
  • "We've seen rates of atopic dermatitis or 'AD' climb," notes Angie Seelal, R-PAC specializing in dermatology with Advanced Dermatology PC .
  • Atopic dermatitis usually starts at a young age, most often under five.
  • "Research has also focused on the skin protein 'filaggrin,' which helps maintain a protective skin barrier," explains Seelal.
  • Bio: Angie Seelal, RPA-C is a Certified Physician Assistant through the National Commission of Certification of Physician Assistants.